Glutamate excitotoxicity in a model of multiple sclerosis.
Glutamate excitotoxicity mediated by the AMPA/kainate type of glutamate receptors damages not only neurons but also the myelin-producing cell of the central nervous system, the oligodendrocyte. In multiple sclerosis, myelin, oligodendrocytes and some axons are lost as a result of an inflammatory attack on the central nervous system. Because glutamate is released in large quantities by activated immune cells, we expected that during inflammation in MS, glutamate excitotoxicity might contribute to the lesion. We addressed this by using the AMPA/kainate antagonist NBQX to treat mice sensitized for experimental autoimmune encephalomyelitis, a demyelinating model that mimics many of the clinical and pathologic features of multiple sclerosis. Treatment resulted in substantial amelioration of disease, increased oligodendrocyte survival and reduced dephosphorylation of neurofilament H, an indicator of axonal damage. Despite the clinical differences, treatment with NBQX had no effect on lesion size and did not reduce the degree of central nervous system inflammation. In addition, NBQX did not alter the proliferative activity of antigen-primed T cells in vitro, further indicating a lack of effect on the immune system. Thus, glutamate excitotoxicity seems to be an important mechanism in autoimmune demyelination, and its prevention with AMPA/kainate antagonists may prove to be an effective therapy for multiple sclerosis.
Pitt
D
D
Department of Pathology, F-121N, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, New York, 10461, USA
Werner
P
P
Raine
C S
CS
D000818:Animals; D001369:Axons / Q000473:pathology; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D018698:Glutamic Acid / Q000633:toxicity*; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation; D051379:Mice; D008815:Mice, Inbred Strains; D009103:Multiple Sclerosis / Q000473:pathology*; D011810:Quinoxalines / Q000627:therapeutic use*; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000502:physiology; D018092:Kainic Acid Receptors / Q000037:antagonists & inhibitors / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology
D018691:Excitatory Amino Acid Antagonists; D018698:Glutamic Acid; D011810:Quinoxalines; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline